Lab mice specifically engineered to grow the HER2 breast cancer tumours, showed remarkable reduction in tumours when treated with the new combination of drugs.
Photo Credit: Yoshikazu Tsuno/AFP)

Exciting Canadian advance against breast cancer

 Nobody had done this before. Researchers at Dalhousie University were testing a combination of two drugs and found they stopped and even killed off a particular type of aggressive breast cancer.

Paola Marignani PhD, lead the research team. She is an associate professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Nova Scotia

Listen

null
Professor Paola Marignani PhD leads a team that for the first time combined two cancer inhibiting drugs to create very exciting breast cancer fightintg results. © supplied

 While the drugs individually had known positive effects against cancer,until now no-one had previously researched them in combination.

Used together AZD8055 and 2-DG were found to have a profound effect against a common and aggressive form of breast cancer known as HER2.

After only a matter of weeks, tumours in the mice treated with the new combination showed remarkable reduction, to the point of non-detection in certain cases.

These results are published in the current issue of the respected science journal, Oncotarget.

null
Novel treatments inhibit tumour growth. Representative mammary tumours harvested from genetically modified mice treated for 21-days with Vehicle (no active chemical), (B) 2-DG only, (C) AZD8055 only and (D) combination of 2-DG plus AZD8055 © Marigniani et al -Dalhousie U

Many such promising research developments often take from 5-10 years to pass through a variety of trials and approvals before they can be used medically for the general public.

But Professor Marignani says because the two drugs in this case are already undergoing individual clinical trials, the period for public approval for a combination use of the drugs may be substantially shortened.

null
© Marigniani et al- Dalhousie U

The research is funded by private donations administered through Dalhousie Medical Research Foundation’s Adopt-a-Researcher programme and grants from the Beatrice Hunter Cancer Research Institute and the Nova Scotia Health Research Foundation.

Other members of the team include doctoral student Rafaela Andrade-Vieira, research assistant Donna Goguen, honours student Heidi Bentley, and collaborator Chris Bowen PhD physics.

Earlier research journal Plos One 2013

Categories: Health, Internet, Science and Technology
Tags: ,

Do you want to report an error or a typo? Click here!

For reasons beyond our control, and for an undetermined period of time, our comment section is now closed. However, our social networks remain open to your contributions.